Behring | Jotup

Behring Welcomes Former USCIS Adjudicator Greg Sheehan to Its EB-5 Team

Retrieved on:

Wednesday, December 7, 2022

IPO, Language, Q&A, Sheehan, Learning, The Q-Music Sessions, Behring, PST, Knowledge, EB-5 Reform and Integrity Act, USCIS, Form, Policy, EB-5, Original North American area codes, Government

BLACKHAWK, Calif., Dec. 7, 2022 /PRNewswire/ --Behring Co. is proud to welcome Greg Sheehan, a former USCIS EB-5 adjudicator and licensed immigration attorney to its team as its Director of EB-5 Platform and USCIS Compliance.

Key Points:

BLACKHAWK, Calif., Dec. 7, 2022 /PRNewswire/ --Behring Co. is proud to welcome Greg Sheehan, a former USCIS EB-5 adjudicator and licensed immigration attorney to its team as its Director of EB-5 Platform and USCIS Compliance.
Sheehan was an adjudicator at IPO from 2018 to 2022 and developed extensive knowledge of this highly regulated space.
"We at Behring Co. are excited to be joined by someone with the extraordinary experience and firsthand working knowledge of USCIS and the EB-5 program as Greg," said Colin Behring, chief executive officer of Behring Co. "He will be an invaluable asset to our team and EB-5 investors."
Regarding his new role at Behring Co., Sheehan said, "The complexity of EB-5 may have walls, but the depths are bottomless.

EB-5 Investments Restart after Behring's Major Legal Victory

Retrieved on:

Saturday, June 25, 2022

BLACKHAWK, Calif., June 25, 2022 /PRNewswire/ -- Behring Co., a vertically integrated real estate developer and the operator of Behring Regional Center ("BRC"), praised the U.S. District Court of the Northern District of California's decision to issue a preliminary injunction, setting aside the deauthorization of EB-5 regional centers by U.S. Citizenship and Immigration Services ("USCIS"). Today's decision by U.S. District Judge Vince Chhabria held that USCIS almost certainly committed legal error when it unilaterally deauthorized designated EB-5 regional centers existing at the time that the EB-5 Reform and Integrity Act of 2022 ("RIA") was enacted into law and required regional centers to apply and receive approval for new designation before allowing them to operate and accept new EB-5 investors. Read the decision here.

Key Points:

The court's order enables Behring Regional Center, and all pre-authorized Regional Centers, to sponsor EB-5 projects.
USCIS is required to accept I-526 petitions filed by new EB-5 investors that make qualified EB-5 investments through BRC.
Behring's EB-5 investment options include lower risk debt-style investments and higher earning preferred equity and common equity, all of which are open to investors immediately.
Behring owns and operates the Behring Regional Center, a USCIS accredited EB-5 regional center with 100-percent investor approval history serving hundreds of investors since 2013.

Behring Co. Files Lawsuit Against USCIS for Wrongfully Terminating EB-5 Regional Center Program

Retrieved on:

Wednesday, February 23, 2022

The lawsuit filed on February 19th claims that the federal agencies are exceeding their authority by unilaterally canceling the EB-5 Regional Center Program after June 30, 2021.

Key Points:

The lawsuit filed on February 19th claims that the federal agencies are exceeding their authority by unilaterally canceling the EB-5 Regional Center Program after June 30, 2021.
A plain reading of the statute demonstrates that Congress established the Regional Center Program as an additional vehicle to facilitate EB-5 investment.
USCIS has now wrongfully associated the expiration of that temporary incentive as the expiration of the EB-5 program as a whole.
Behring owns and operates the Behring Regional Center, a USCIS accredited EB-5 regional center with 100-percent investor approval history serving hundreds of investors since 2013.

When The EB-5 Regional Center Program Resumes, We Will Be Ready

Retrieved on:

Friday, August 6, 2021

DALLAS, Aug. 06, 2021 (GLOBE NEWSWIRE) -- On June 30, 2021, the EB-5 Regional Center Program (EB-5 Program) expired after many in the industry thought there would be reauthorization through the EB-5 Reform and Integrity Act (Senate Bill S.831 or the “Bill”), which had bipartisan support from Senators Grassley (R- Iowa) and Leahy (D – Vermont). When the Bill was proposed on the Senate floor for a unanimous consent vote through the hotline procedure, Senator Lindsay Graham objected and therefore it did not pass. This was a shock to the many in the industry, since it appeared the legislation was going to pass based on chatter coming out of Congressional offices.

Key Points:

When the world found out about this ruling, with only one week before the EB-5 Program lapsed, EB-5 investors raced to invest into EB-5 regional center projects at the previous lower $500,000 investment amount.
CMB Regional Centers will be ready when the program is reauthorized, will you?
CMB has been involved in EB-5 since 1997, when CMB Export, LLC was first authorized as an EB-5 regional center.
The regional center program has seen many extensions throughout the past 30 years and has experienced a few short lapses in congressional authorization.

Behring Co. Wins Landmark Decision to Revive EB-5 Immigrant Investor Visa Program

Retrieved on:

Wednesday, June 23, 2021

Other Construction & Property, Construction & Property, Professional services, Finance, Nationality, Residency, Foreign direct investment, EB-5 visa, Behring

The program required a minimum $500,000 investment in a U.S. business that would create at least 10 full-time jobs for American workers.

Key Points:

The program required a minimum $500,000 investment in a U.S. business that would create at least 10 full-time jobs for American workers.
We are strong supporters of positive EB-5 reform and modernization, but the 2019 rule did none of that, said Colin Behring, CEO of Behring Co.
Although imperfect, the EB-5 program has been one of the most successful and efficient job creation programs the federal government has ever enacted.
Behring owns and operates the Behring Regional Center, a USCIS accredited EB-5 regional center with 100-percent investor approval history serving hundreds of investors since 2013.

Lyfebulb and CSL Behring Announce the Winner of the 2021 Transplant Innovation Challenge

Retrieved on:

Friday, May 14, 2021

CSL Behring, Behring, Companies, CSL Limited, CSL, LinkedIn

"That\'s the very essence of this challenge and why we are excited about seeing how all of these incredible ideas may someday make a difference for patients."

Key Points:

"That\'s the very essence of this challenge and why we are excited about seeing how all of these incredible ideas may someday make a difference for patients."
See Lyfebulb.com , TransplantLyfe.com , Facebook , Twitter , Instagram , LinkedIn , and Karin Hehenberger LinkedIn .\nCSL Behring is a global biotherapeutics leader driven by its promise to save lives.
The parent company, CSL Limited (ASX:CSL;USOTC:CSLLY), headquartered inMelbourne, Australia, employs more than 27,000 people, and delivers its life-saving therapies to people in more than 100 countries.
For inspiring stories about the promise of biotechnology, visit Vita CSLBehring.com/vita and follow us on Twitter.com/CSLBehring .\n'

uniQure Presents HOPE-B Clinical Data Demonstrating Clinical Benefit in Hemophilia B Patients with Pre-existing Antibodies to AAV5 Vector

Retrieved on:

Thursday, May 13, 2021

Branches of biology, Life sciences, Biology, CSL Behring, Applied genetics, Neutralizing antibody, Antibody, Gene therapy, Behring, Therapy

These data were previously presented at a medical meeting late last year.\n\xe2\x80\x9cThe ASGCT presentation highlights these initial HOPE-B data that demonstrate the successful treatment with an AAV5 gene therapy of patients with pre-existing NAbs,\xe2\x80\x9d stated Ricardo Dolmetsch , Ph.D., president of Research and Development at uniQure.

Key Points:

These data were previously presented at a medical meeting late last year.\n\xe2\x80\x9cThe ASGCT presentation highlights these initial HOPE-B data that demonstrate the successful treatment with an AAV5 gene therapy of patients with pre-existing NAbs,\xe2\x80\x9d stated Ricardo Dolmetsch , Ph.D., president of Research and Development at uniQure.
\xe2\x80\x9cPatients in the trial who may not have been eligible for other gene therapies because of pre-existing neutralizing antibodies have achieved similar results with etranacogene dezaparvovec compared to those who did not have pre-existing NAbs.
Mean FIX activity at 26 weeks was 32.7 percent in participants with NAbs versus 41.3 percent in those without.
uniQure and CSL Behring have entered into a commercialization and license agreement providing CSL Behring exclusive global commercialization rights to etranacogene dezaparvovec.

uniQure Announces First Quarter 2021 Financial Results and Highlights Recent Company Progress

Retrieved on:

Monday, May 10, 2021

Merck Group, Pharmaceutical companies, Companies, Merck Serono, Life sciences, Amgen, Serono, CSL Behring, Behring, Merck

Phase I/II clinical trial of AMT-130 for Huntington\xe2\x80\x99s disease, with initiation of second dose cohort and European Phase Ib/II expected in second half of 2021 ~\n~ Research & Development Day to be held Tuesday, June 22, 2021 ~\nLEXINGTON, Mass.

Key Points:

Phase I/II clinical trial of AMT-130 for Huntington\xe2\x80\x99s disease, with initiation of second dose cohort and European Phase Ib/II expected in second half of 2021 ~\n~ Research & Development Day to be held Tuesday, June 22, 2021 ~\nLEXINGTON, Mass.
\xe2\x80\x9cIn the second half of the year, we expect to begin patient enrollment in the second cohort of AMT-130 and to initiate our open-label European study of AMT-130.
Mr. Caloz joins the Company with nearly 20 years of global operations experience in the biopharma industry, including CSL Behring, Merck-Serono, Abgenix and Amgen.
Forward-looking statements are based on management\'s beliefs and assumptions and on information available to management only as of the date of this press release.

CSL Behring Announces Closing of Global Commercialization and License Agreement with uniQure for etranacogene dezaparvovec

Retrieved on:

Thursday, May 6, 2021

CSL Behring, CSL Limited, Behring, CSL, Companies, Health care, Industry economics)

"Etranacogene dezaparvovechas the potential to be the first-ever gene therapy approved for hemophilia B and to help CSL Behring deliver on our ongoing commitment to improving the lives of those living with hemophilia B.

Key Points:

"Etranacogene dezaparvovechas the potential to be the first-ever gene therapy approved for hemophilia B and to help CSL Behring deliver on our ongoing commitment to improving the lives of those living with hemophilia B.
The company\'s products are also used in cardiac surgery, burn treatment and to prevent hemolytic disease of the newborn.\nCSL Behring operates one of the world\'s largest plasma collection networks, CSL Plasma.
The parent company, CSL Limited (ASX:CSL;USOTC:CSLLY), headquartered in Melbourne, Australia, employs more than 27,000 people, anddelivers its life-saving therapies to people in more than 100 countries.
For inspiring stories about the promise of biotechnology, visit Vita CSLBehring.com/vita and follow us on Twitter.com/CSLBehring .\n'

CSL Behring Announces Closing of Global Commercialization and License Agreement with uniQure for etranacogene dezaparvovec

Retrieved on:

Thursday, May 6, 2021

CSL Behring, CSL Limited, Behring, CSL, Companies, Health care, Industry economics)

"Etranacogene dezaparvovechas the potential to be the first-ever gene therapy approved for hemophilia B and to help CSL Behring deliver on our ongoing commitment to improving the lives of those living with hemophilia B.

Key Points:

"Etranacogene dezaparvovechas the potential to be the first-ever gene therapy approved for hemophilia B and to help CSL Behring deliver on our ongoing commitment to improving the lives of those living with hemophilia B.
The company\'s products are also used in cardiac surgery, burn treatment and to prevent hemolytic disease of the newborn.\nCSL Behring operates one of the world\'s largest plasma collection networks, CSL Plasma.
The parent company, CSL Limited (ASX:CSL;USOTC:CSLLY), headquartered in Melbourne, Australia, employs more than 27,000 people, anddelivers its life-saving therapies to people in more than 100 countries.
For inspiring stories about the promise of biotechnology, visit Vita CSLBehring.com/vita and follow us on Twitter.com/CSLBehring .\n'